FDA approves Johnson & Johnson’s rare disease drug that’s expected to compete with argenx and UCB
Article Title: FDA approves Johnson & Johnson’s rare disease drug that’s expected to compete with argenx and UCB Publication Date: April 30, 2025 On April 30, 2025, Johnson & Johnson received an approval from the FDA for its new rare…